Durvalumab May Be Effective as Second Line Therapy in Urothelial Carcinoma

Share this content:
There are few second line therapies that provide clinical benefit for those with relapsed stage IV urothelial carcinoma.
There are few second line therapies that provide clinical benefit for those with relapsed stage IV urothelial carcinoma.

Patients with locally advanced/metastatic urothelial carcinoma (UC) may experience clinical benefit with durvalumab, according to a study published in JAMA Oncology.1

Patients with relapsed stage IV UC after chemotherapy experience poor outcomes, and there is a lack of well-established second line therapies that provide clinical benefit for this patient population. A previous interim analysis of this study demonstrated that durvalumab is well tolerated and has antitumor effects for UC.

For this phase 1/2 clinical study (ClinicalTrials.gov Identifier: NCT01693562), researchers identified 191 patients with advanced/metastatic UC and administered intravenous durvalumab 10 mg/kg every 2 weeks.

At median overall follow-up of 5.78 months, the ORR was 17.8% (95% CI, 12.7%-24.0%), including 7 complete responses. The median time to response was 1.41 months and median duration of response was not reached by follow-up. Early and durable response to therapy were observed in patients regardless of high and low (ORR, 27.6%; 95% CI, 19.0%-37.5) or negative (ORR, 5.1%; 95% CI, 1.4%-12.5%) programmed-cell-death-ligand-1 (PD-L1) expression.

The median progression-free survival was 1.5 months (95%, 1.4-1.9 months). Overall survival was 18.2 months (95% CI, 8.1-not estimable), and the 1-year overall survival rate was 55% (95% CI, 44%-65%).

Grade 3 to 4 treatment-related AEs occurred in 6.8% of patients, and grade 3 to 4 immune-mediated AEs occurred in 2.1% of patients. Treatment related adverse events (AE) led to discontinuation for 1.6% of patients, and 2 patients who experienced immune-mediated AEs died.

The study authors concluded by saying that the early clinical efficacy and favorable safety profile of durvalumab “have formed the basis for its recent regulatory approval and positioning as a standard of care (alongside atezoluzumab and nivolumab) in this setting.”

Reference

  1. Powles T, O'Donnell PH, Massard C, et al. Efficacy and safety of durvalumab in locally advanced or metastatic urothelial carcinoma [published online August 17, 2017]. JAMA Oncol. doi: 10.1001/jamaoncol.2017.2411 

Related Resources

You must be a registered member of Cancer Therapy Advisor to post a comment.

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs

Sign Up for Free e-newsletters